CD274 and neoplasm: In some preclinical studies, anti-TIM-3 therapy can improve anti-tumor efficacy, and combination therapy with anti-PD-1 or anti-PD-L1 can significantly reduce tumor burden and improve anti-tumor immune responses (24).